Apexigen Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 31

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $10.7M

Apexigen General Information

Description

Apexigen Inc is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient's immune system to combat and eradicate cancer.. The company's pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is in clinical development, and also includes several preclinical stage immune-oncology programs.

Contact Information

Website
www.apexigen.com
Formerly Known As
Apex Biotherapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Pyxis Oncology
Primary Office
  • 900 Industrial Road
  • Suite C
  • San Carlos, CA 94070
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apexigen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 23-Aug-2023 $10.7M 00000 000.00 Completed Generating Revenue
7. PIPE 24-Jan-2023 00.00 00000 Completed Generating Revenue
6. PIPE 01-Aug-2022 0000 00000 00000 Completed Generating Revenue
5. Reverse Merger 01-Aug-2022 00000 00000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 24-Mar-2020 0000 00000 00000 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 08-Aug-2018 0000 0000 00000 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series B) 22-Jul-2016 $15M $35M 00000 Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A1) 08-Aug-2013 $20M $20M 000.00 Completed Startup
To view Apexigen’s complete valuation and funding history, request access »

Apexigen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series A2 12,652,762 $0.001000 $0.02 $0.2 $0.2 1x $0.2 6.69%
Series A1 39,196,116 $0.001000 $0.04 $0.51 $0.51 1x $0.51 20.73%
To view Apexigen’s complete cap table history, request access »

Apexigen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Apexigen Inc is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of ant
Drug Discovery
San Carlos, CA
31 As of 2023
00000
00.00 0000-00-00
000000&0 00000

000000

inim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
0000 000000000
Oxford, United Kingdom
00 As of 0000
000.00
0000000000 000.00

000000

do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
0000 000000000
Boston, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Apexigen Competitors (102)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Theolytics Venture Capital-Backed Oxford, United Kingdom 00 000.00 0000000000 000.00
0000000 0000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
0000000 Venture Capital-Backed Leiden, Netherlands 00 000.00 0000000000 0 000.00
00000 00000 000000 Private Equity-Backed Geneva, Switzerland 00 00000 00000000000 00000
00000000000 000000 Formerly VC-backed Newark, CA 000 00000 00000000 00000
You’re viewing 5 of 102 competitors. Get the full list »

Apexigen Patents

  • 95

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 7

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Apexigen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4110819-A1 Anti-sirpa antibodies and methods of use Pending 28-Feb-2020 00000000000
US-20230340112-A1 Anti-sirpa antibodies and methods of use Pending 28-Feb-2020 00000000000
AU-2020348224-A1 Anti-tnfr2 antibodies and methods of use Pending 17-Sep-2019 00000000000
CA-3154643-A1 Anti-tnfr2 antibodies and methods of use Pending 17-Sep-2019 00000000000
EP-4031177-A2 Anti-tnfr2 antibodies and methods of use Pending 17-Sep-2019 C07K16/2878
To view Apexigen’s complete patent history, request access »

Apexigen Executive Team (11)

Name Title Board Seat Contact Info
Xiaodong Yang Ph.D Chief Executive Officer & Board Member
Amy Wong Senior Vice President, Finance and Operations
You’re viewing 2 of 11 executive team members. Get the full list »

Apexigen Board Members (13)

Name Representing Role Since
Samuel Wertheimer Ph.D Apexigen Board Member 000 0000
Xiaodong Yang Ph.D Apexigen Chief Executive Officer & Board Member 000 0000
You’re viewing 2 of 13 board members. Get the full list »

Apexigen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Apexigen Former Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
3E Bioventures (China) Venture Capital Minority 000 0000 000000 0
AimTop Ventures Venture Capital Minority 000 0000 000000 0
Amkey Ventures Venture Capital Minority 000 0000 000000 0
Brightway Future Capital Venture Capital Minority 000 0000 000000 0
Brookline Capital Acquisition Special Purpose Acquisition Company (SPAC) Minority 000 0000 000000 0
You’re viewing 5 of 24 investors. Get the full list »

Apexigen Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Brookline Capital Acquisition 01-Aug-2022 0000000000 Special Purpose Acquisition Company (SPAC) 00000000
To view Apexigen’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Apexigen Subsidiaries (1)

Company Name Industry Location Founded
Brookline Capital Acquisition Special Purpose Acquisition Company (SPAC) New York, NY 0000
To view Apexigen’s complete subsidiaries history, request access »